Phase I trial of rosiglitazone in FSGS: I. Report of the FONT Study Group (Q37042128)

17 August 2017

Phase I trial of rosiglitazone in FSGS: I. Report of the FONT Study Group (English)

1 reference

17 August 2017

phase I clinical trial

0 references

1 reference

Allison Eddy

7

0 references

Howard Trachtman

object named as

Howard Trachtman

11

0 references

Jeffrey B. Kopp

object named as

Jeffrey B Kopp

9

0 references

Daniel C. Cattran

10

object named as

Daniel Cattran

1 reference

17 August 2017

2

Debbie S Gipson

1 reference

17 August 2017

Melanie S Joy

1

1 reference

17 August 2017

Mary Dike

3

1 reference

17 August 2017

Leslie Powell

4

1 reference

17 August 2017

Amber Thompson

5

1 reference

17 August 2017

Suzanne Vento

6

1 reference

17 August 2017

Agnes B Fogo

8

1 reference

17 August 2017

10 December 2008

1 reference

Clinical Journal of the American Society of Nephrology

17 August 2017

1 reference

17 August 2017

4

1 reference

17 August 2017

1

1 reference

17 August 2017

39-47

1 reference

Emerging evidence of the impact of kidney disease on drug metabolism and transport

17 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2615712

Mechanism-based concepts of size and maturity in pharmacokinetics

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2615712

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2615712

Effects of serum from patients with chronic renal failure on rat hepatic cytochrome P450

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2615712

Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2615712

Characterization of hepatic cytochrome p4503A activity in patients with end-stage renal disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2615712

Rosiglitazone monotherapy is effective in patients with type 2 diabetes

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2615712

Reduction of proteinuria by rosiglitazone in non-diabetic renal disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2615712

Effect of various diuretic treatments on rosiglitazone-induced fluid retention

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2615712

Apoptosis and proliferation of cultured mesangial cells isolated from kidneys of rosiglitazone-treated pregnant diabetic rats

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2615712

PPARgamma agonists exert antifibrotic effects in renal tubular cells exposed to high glucose

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2615712

Pioglitazone inhibits cell growth and reduces matrix production in human kidney fibroblasts.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2615712

Pharmacokinetics of rosiglitazone in patients with varying degrees of renal insufficiency

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2615712

Rosiglitazone reduces urinary albumin excretion in type II diabetes

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2615712

Automated high-performance liquid chromatography method for the determination of rosiglitazone in human plasma

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2615712

Peroxisome proliferator-activated receptor-gamma agonist is protective in podocyte injury-associated sclerosis

4 September 2018

1 reference

12 December 2020

Hemodialysis acutely improves hepatic CYP3A4 metabolic activity

1 reference

12 December 2020

Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria

1 reference

12 December 2020

Role of parathyroid hormone in the downregulation of liver cytochrome P450 in chronic renal failure

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype

1 reference

12 December 2020

Cardiovascular safety of rosiglitazone

1 reference

12 December 2020

Decreased in vivo metabolism of drugs in chronic renal failure

1 reference

12 December 2020

Identifiers

DOI

10.2215/CJN.02310508

1 reference

17 August 2017

1 reference

17 August 2017

PubMed publication ID

19073787

1 reference